Latest Secondary Hyperparathyroidism (SHPT) News
The surgery reduced the risk of death from any cause by 37%, meta-analysis shows.
Over 33 months, the 25-hydroxyvitamin D level of ergocalciferol recipients increased significantly from 15.14 to 37.32 ng/mL.
The risk of peripheral arterial disease was 34% lower for end-stage renal disease patients who underwent the procedure.
SHPT risk was 4 times higher among patients taking furosemide vs hydrochlorothiazide.
Researchers highlighted the benefit of iPTH monitoring.
The debate continues on how best to use parathyroidectomy to treat severe SHPT.
Calcifediol formulation is indicated for CKD stage 3 or 4 patients with secondary hyperparathyroidism associated with vitamin D insufficiency.
No new safety concerns observed in a 52-week extension trial of etelcalcetide in hemodialysis with secondary hyperparathyroidism.
Paricalcitol-based protocol includes limited use of calcium-based phosphate binders.
The control of phosphorus is underappreciated, for example.
Researchers found insignificant differences between the 2 surgeries in SHPT persistence and recurrence.
Treatment with the medication reduced the risk of death by half among patients with iPTH of 500 pg/mL or above.
An academic hemodialysis center realized cost savings from vitamin D receptor activator therapy after converting to oral calcitriol -- without negative impact on SHPT control.
Iranian study of hemodialysis patients with secondary hyperparathyroidism finds no significant correlation.
Intact parathyroid hormone levels fell significantly in all patients who underwent total Ptx with autotransplant and 91.6% of subtotal Ptx patients.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)